Glufosfamide is dead, long live glufosfamide!
This article was originally published in Scrip
Executive Summary
Eleison Pharmaceuticals has begun a new Phase III trial of the alkylating agent glufosfamide in second-line pancreatic cancer, even though it failed in the same setting a few years ago.